141 related articles for article (PubMed ID: 6529804)
1. Studies on hypolipidemic agents. III. Comparison of the hypolipidemic properties of 5-tridecylpyrazole-3-carboxylic acid and clofibrate.
Seki K; Fukuda M; Isegawa J; Ohki M
Chem Pharm Bull (Tokyo); 1984 Oct; 32(10):4103-9. PubMed ID: 6529804
[No Abstract] [Full Text] [Related]
2. Studies on hypolipidemic agents. IV. Influence of a new hypolipidemic agent, 5-tridecylpyrazole-3-carboxylic acid, on cholesterol metabolism in rats.
Seki K; Fukuda M; Ohki M
Chem Pharm Bull (Tokyo); 1985 Nov; 33(11):5036-41. PubMed ID: 3830430
[No Abstract] [Full Text] [Related]
3. Studies on hypolipidemic agents. V. Influence of 5-tridecylpyrazole-3-carboxylic acid, a new hypolipidemic agent, on intestinal cholesterol absorption in rats.
Seki K; Watanabe T; Suga T
Chem Pharm Bull (Tokyo); 1988 Mar; 36(3):1117-21. PubMed ID: 3409399
[No Abstract] [Full Text] [Related]
4. Effects of hypolipidemic drugs on hepatic CoA.
Halvorsen O
Biochem Pharmacol; 1983 Mar; 32(6):1126-8. PubMed ID: 6838659
[No Abstract] [Full Text] [Related]
5. Action of tiadenol and clofibrate on biliary excretions of cholesterol and bile salts in rats.
Fredj G; Clenet M; Cuchet P; Rousselet F; Rozé C
Digestion; 1979; 19(4):228-36. PubMed ID: 478204
[TBL] [Abstract][Full Text] [Related]
6. Hypolipidemic effects of dietary 7-oxo-24,25-dihydrolanosterol.
Sonoda Y; Sato Y
J Pharmacobiodyn; 1985 Jul; 8(7):518-24. PubMed ID: 4067814
[TBL] [Abstract][Full Text] [Related]
7. Changes in lipid metabolizing enzymes of hepatic subcellular fractions from rats treated with tiadenol and clofibrate.
Berge RK; Bakke OM
Biochem Pharmacol; 1981 Aug; 30(16):2251-6. PubMed ID: 7295339
[No Abstract] [Full Text] [Related]
8. [Comparative effects of clofibrate and tiadenol on the metabolism of cholesterol in rats and hamsters. I. Comparative action of clofibrate and tiadenol on hepatic and intestinal biosynthesis of cholesterol in hamsters and rats].
Rousselet F; Fredj G; Clenet M
Ann Pharm Fr; 1986; 44(4):269-76. PubMed ID: 3566092
[No Abstract] [Full Text] [Related]
9. Effect of Wy-14,643 on cholesterol metabolism in normal and hypercholesterolemic rats.
Tomarelli RM; Bauman LM; Savini S
Atherosclerosis; 1978 Aug; 30(4):301-11. PubMed ID: 708488
[No Abstract] [Full Text] [Related]
10. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat.
Rozé C; Cuchet P; Souchard M; Vaille C; Debray C
Eur J Pharmacol; 1977 May; 43(1):57-64. PubMed ID: 862664
[TBL] [Abstract][Full Text] [Related]
11. Effects of clofibrate and tiadenol on the elimination of lipids and bile acids in rat bile.
Cuchet P; Morrier C; Cand F; Keriel C
Lipids; 1981 Oct; 16(10):732-8. PubMed ID: 7300592
[TBL] [Abstract][Full Text] [Related]
12. Hypolipidemic effect of ethyl all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E) in rats.
Mizuguchi K; Yano T; Kojima M; Tanaka Y; Ishibashi M; Masada A; Sato M; Mizota M; Fukutake K; Saito Y
Jpn J Pharmacol; 1992 Jul; 59(3):307-12. PubMed ID: 1434127
[TBL] [Abstract][Full Text] [Related]
13. Effects of soybean phospholipid, chlorella phospholipid, and clofibrate on collagen and elastin synthesis in the aorta and on the serum and liver lipid contents in rats.
Hashimoto S; Setoyama T; Yokokura T; Mutai M
Exp Mol Pathol; 1982 Feb; 36(1):99-106. PubMed ID: 7198996
[No Abstract] [Full Text] [Related]
14. Three hypolipidemic drugs increase hepatic palmitoyl-coenzyme A oxidation in the rat.
Lazarow PB
Science; 1977 Aug; 197(4303):580-1. PubMed ID: 195342
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
Morishita S; Saito T; Hirai Y; Shoji M; Mishima Y; Kawakami M
J Med Chem; 1988 Jun; 31(6):1205-9. PubMed ID: 3163736
[TBL] [Abstract][Full Text] [Related]
16. Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: I. Chow-fed animals.
O'Brien M; Patel ST; Mukhopadhyay A; Newman HA; Feller DR; Kokrady SS; Witiak DT; Lanese RR; Rice JC
Lipids; 1981 Dec; 16(12):903-11. PubMed ID: 7329211
[TBL] [Abstract][Full Text] [Related]
17. Effects of N-(4-methylbenzylthiocarbonyl)-L-phenylalanine (KF 1492), a new hypolipidemic drug, and clofibrate on lipids metabolism.
Ishii A; Deguchi T; Marumo H; Tanaka M
J Pharmacobiodyn; 1983 Mar; 6(3):170-6. PubMed ID: 6410039
[TBL] [Abstract][Full Text] [Related]
18. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid.
Orton TC; Parker GL
Drug Metab Dispos; 1982; 10(2):110-5. PubMed ID: 6124394
[TBL] [Abstract][Full Text] [Related]
19. Prevention of CeCl3-induced hepatotoxicity by hypolipidemic compounds.
Tuchweber B; Salas M
Arch Toxicol; 1978 Dec; 41(3):223-32. PubMed ID: 736793
[TBL] [Abstract][Full Text] [Related]
20. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
Reddy J; Svoboda D; Azarnoff D
Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
